

Jenoptik to acquire Berliner Glas Medical and SwissOptic

Disclaimer



This presentation can contain forward-looking statements that are based on current expectations and certain assumptions of the management of the Jenoptik Group. A variety of known and unknown risks, uncertainties and other factors can cause the actual results, the financial situation, the development or the performance of the company to be materially different from the announced forward-looking statements. Such factors can be, among others, pandemic diseases, changes in currency exchange rates and interest rates, the introduction of competing products or the change of the business strategy. The company does not assume any obligation to update such forward-looking statements in this document in the light of future developments.

October 2021 2



Berliner Glas Medical / SwissOptic at a glance







~70
years of high
precision optics
experience

Key markets:

Medical technology Semiconductor Metrology

Substantial expansion

of combined global production facilities

Highly reputable

premium product provider

~500 employees

~130m euros 2022E Revenue


>10%
Mid-term
revenue CAGR

Attractive margin profile

¹ Comprises SwissOptic AG (Switzerland) and SwissOptic (Wuhan) Co. Ltd (China).

Berliner Glas Medical / SwissOptic detailed overview






Medical Technology (~53%)

1 Based on latest audited financials

Berliner Glas Medical / SwissOptic acquisition – Transaction rationale and highlights






October 2021 6




Strengthening of Jenoptik's global photonics / L&O business



Jenoptik revenue share by division¹⁾




Pro-forma Jenoptik revenue share by division¹⁾ (incl. Berliner Glas Medical and SwissOptic)





Footprint expansion in highly attractive markets – particularly semicon and medical technology





Medical Technology

Broadening of product and technology offering




Medical Technology



Jenoptik's existing medical technology business will almost double

- Berliner Glas Medical adds two new complementary application areas (dental, robotic surgery) with technological proximity to existing Jenoptik technology base (cameras, optical components)
- SwissOptic's ophthalmology and life science businesses with similar OEM customer base, thus increasing Jenoptik's relevance to respective customers



Semicon



Strengthening offering for major semicon customers

- Complementary product portfolios resulting in a comprehensive combined portfolio
- Applying Jenoptik's know-how in optics design & manufacturing to SwissOptics's semicon portfolio will allow Jenoptik to better address high customer requirements
- Increased flexibility and efficiency in product development and manufacturing ramp-ups due to similar R&D capabilities, supplier base and customer experience
- Further strengthening trusted long-standing relationship with ASML

Strengthening of Jenoptik's Medical Technology and Semiconductor Equipment business

1) Revenue split based on latest audited financials



Expansion of global manufacturing footprint incl. China



additional production facilities



~110 FTE

Heerbrugg, Switzerland



~290 FTE

Wuhan, China




~100 FTE

Expansion

of combined production area incl. cleanroom capacity

> ~500 employees





- Significant growth potential for Jenoptik from SwissOptic's Wuhan production facility
- Additional production capacities in highly attractive optics locations in Berlin and Rhine Valley

Upside potential through well-defined synergy opportunities





Procurement

Cost synergy potential via joint procurement (higher volumes)



Production optimization

Additional production capacity to optimize utilization levels across production footprint



Research & Development

More efficient R&D with scale and development cost savings



Wuhan facility

Expansion potential of Wuhan facility beyond current set-up

October 2021

11

Highly attractive deal economics and sustainable profitable growth



~300m euros purchase price

Accretive In 2022

Accelerated growth profile

Attractive margin profile

Financing

with cash on balance sheet and undrawn credit lines ~3x


post-acquisition leverage, still in line with target leverage **Dec 2021**

expected closing, after approval by German Federal Cartel Office

Acquisition accelerates growth and strengthens Jenoptik's market position as a leading global photonics group







Thank you for your attention!